Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00132652 | Switching Therapy From Lamivudine to Telbivudine Versus Continued Lamivudine in Adults With Chronic Hepatitis B | PHASE3 | COMPLETED | 240 | — | — | Feb 1, 2005 | Dec 1, 2006 | Feb 23, 2017 | 14 | United States, Australia +9 |
| Name | Type | Description |
|---|---|---|
| Lamivudine | DRUG | - |
| Telbivudine | DRUG | - |
Inclusion Criteria: * Documented clinical history compatible with chronic hepatitis B * Patient has compensated liver disease * Patient has received previous treatment with lamivudine for a duration of at least 3 months and not more than 12 months Other protocol-defined inclusion criteria may appl...